Publicaciones
-
Ortiz-Maldonado V, Rives-Solà S, Español-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L, Giné E, Pascal M, Díaz-Beyá M, Castella M, Català-Temprano A, Faura A, Rodríguez-Lobato LG, Oliver-Caldes A, Martínez-Roca A, Rovira M, González-Navarro EA, Ortega JR, Cid J, Lozano M, Garcia-Rey E, Fernández S, Castro P, Jordán-García I, Villamor N, Aymerich M, Torrebadell-Burriel M, Deyà-Martinez A, Fernández de Larrea C, Benitez-Ribas D, Trias E, Varea S, Calvo G, Esteve J, Urbano-Ispizua A, Juan-Otero M and Delgado J.
Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
Journal for ImmunoTherapy of Cancer . 9(12): 3644. Nº de citas: 15
-
Vega-García N, Pérez-Jaume S, Esperanza-Cebollada E, Vicente-Garces C, Torrebadell-Burriel M, Jiménez-Velasco A, Ortega M, Llop M, Abad L, Vagace JM, Minguela A, Pratcorona M, Sánchez-Garcia J, García-Calderon CB, Gómez-Casares MT, Martín-Clavero E, Escudero A, Riñón M, Muñoz L, Velasco MR, García-Morín M, Català-Temprano A, Pascual A, Velasco P, Fernandez JM, Lassaletta A, Fuster JL, Badell I, Molinos-Quintana A, Molinés A, Guerra-Garcia P, Pérez-Martínez A, García-Abós M, Robles R, Pisa S, Adán R, Díaz de Heredia C, Dapena JL, Rives-Solà S, Ramirez M and Camós-Guijosa M.
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Frontiers in pediatrics . 8: 614521-614521. Nº de citas: 5
-
Ortíz-Maldonado V, Rives-Solà S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Jordi Cid Colom, Garcia-Rey E, Llanos C, Torrebadell-Burriel M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català-Temprano A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordán-García I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan-Otero M and Delgado J.
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies
MOLECULAR THERAPY . 29(2): 636-644. Nº de citas: 88
-
Deyà-Martinez A, Alonso-Saladrigues A, García, AP, Faura, A, Torrebadell-Burriel M, Vlagea, A, Català-Temprano A, Esteve-Solé A, Juan-Otero M, Rives-Solà S and Alsina L.
Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia
BONE MARROW TRANSPLANTATION . 56(2): 376-386. Nº de citas: 12
-
Vega-García N, Benito R, Esperanza-Cebollada E, Llop M, Robledo C, Vicente-Garces C, Alonso J, Barragán E, Fernandez-Isern G, Hernández-Sánchez JM, Martín-Izquierdo M, Maynou-Fernández J, Minguela A, Montaño A, Ortega M, Torrebadell-Burriel M, Cervera J, Sánchez J, Jiménez-Velasco A, Riesco S, Hernández-Rivas JM, Lassaletta Á, Fernández JM, Rives-Solà S, Dapena JL, Ramírez M and Camós-Guijosa M.
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia
Journal of Personalized Medicine . 10(4): 244. Nº de citas: 1
-
Sánchez-Martínez D, Baroni ML, Gutierrez-Agüera F, Roca-Ho H, Blanch-Lombarte O, González-García S, Torrebadell-Burriel M, Junca J, Ramírez-Orellana M, Velasco-Hernández T, Bueno C, Fuster JL, Prado JG, Calvo J, Uzan B, Cools J, Camós-Guijosa M, Pflumio F, Toribio ML and Menéndez P.
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Blood . 133(21): 2291-2304. Nº de citas: 83
-
Pascual-Pastó G, Bazan-Peregrino M, Gene-Olaciregui N, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa MG, Paco-Mercader S, Vilà-Ubach M, Cuadrado-Vilanova M, Castillo H, Botteri G, García-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell-Burriel M, Roldan-Molina M, König A, Suñol M, Claverol J, Lavarino C, de Torres C, Fu L, Radvanyi F, Munier FL, Català-Mora J, Mora J, Alemany R, Cascallo M, Chantada G and Carcaboso AM.
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
SCIENCE TRANSLATIONAL MEDICINE . 11(476): 9321. Nº de citas: 76
-
Torrebadell-Burriel M, Diaz-Beya M, Kalko SG, Pratcorona M, Nomdedeu J, Navarro A, Gel B, Brunet S, Sierra J, Camós-Guijosa M and Esteve J.
A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
LEUKEMIA & LYMPHOMA . 59(10): 2394-2404. Nº de citas: 14
-
Vega-García N, Malatesta R, Estella-Aguado MC, Pérez-Jaume S, Esperanza-Cebollada E, Torrebadell-Burriel M, Català-Temprano A, Gassiot S, Berrueco R, Ruiz-Llobet A, Alonso-Saladrigues A, Mesegue-Meda M, Pont-Martí S, Rives-Solà S and Camós-Guijosa M.
Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases
BRITISH JOURNAL OF HAEMATOLOGY . 182(4): 542-553. Nº de citas: 7
-
Pascual-Pastó G, Gene-Olaciregui N, Opezzo JAW, Castillo-Ecija H, Cuadrado-Vilanova M, Paco-Mercader S, Rivero EM, Vilà-Ubach M, Restrepo-Perdomo CA, Torrebadell-Burriel M, Suñol M, Schaquevich P, Mora J, Bramuglia GF, Chantada G and Carcaboso AM.
Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier
JOURNAL OF CONTROLLED RELEASE . 264: 34-44. Nº de citas: 13